The Potential Drug Target or Biomarker CNE9 Enhancer: Unlocking the Power of SHOX

Target Name: CNE9

NCBI ID: G108410392

CNE9

Other Name(s): CNE9 enhancer downstream of SHOX | ECS4/CNE9 | ECS4

The Potential Drug Target or Biomarker CNE9 Enhancer: Unlocking the Power of SHOX

The SHOX gene is a key regulator of cell proliferation and growth, and it has been implicated in numerous diseases, including cancer. The SHOX gene has four splice variants, each with distinct functional differences. One of these variants, SHOX10, has been particularly well-studied and is considered a promising drug target in the field of cancer. In this article, we will explore the potential drug target or biomarker qualities of the CNE9 enhancer downstream of SHOX, and its implications for cancer treatment.

The SHOX gene and its variants

The SHOX gene is a member of the TGF-β signaling pathway, which is a critical pathway involved in cell growth, differentiation, and survival. The SHOX gene has four splice variants, each with a distinct 5' and 3' splice site. The most abundant variant is SHOX1, which is predominantly expressed in human tissues, including lung, breast, and ovarian cancer. The second most abundant variant is SHOX2, which is expressed in tissues similar to SHOX1 but at lower levels. The third variant, SHOX3, is expressed in tissues including the brain and pancreas, and the fourth variant, SHOX4, is expressed in tissues such as skin and heart.

In addition to the four main splice variants, there are also rare variants of the SHOX gene that have been identified. These variants include SHOX5, SHOX6, and SHOX7, which are predominantly expressed in mouse tissues.

The functional importance of the SHOX gene

The SHOX gene has been shown to play a crucial role in regulating cell proliferation and growth. SHOX1 and SHOX2 have been shown to promote the growth and survival of cancer cells, while SHOX3 and SHOX4 have been shown to have a more limited role in these processes.

One of the most significant functions of the SHOX gene is its role in the regulation of cell proliferation. The SHOX gene has been shown to encode a transcription factor that can induce the expression of genes involved in cell growth and survival. In addition, the SHOX gene has also been shown to play a role in regulating cell apoptosis, or programmed cell death, which is a natural mechanism that helps remove damaged or dysfunctional cells from the body.

The potential drug target or biomarker qualities of the CNE9 enhancer downstream of SHOX

The CNE9 gene is a known enhancer of the SHOX gene and has been shown to play a role in the regulation of cell proliferation and apoptosis. The CNE9 gene has been shown to enhance the transcriptional activity of the SHOX gene, particularly in the context of cell proliferation.

One of the most promising aspects of the CNE9 gene is its potential as a drug target. The CNE9 gene has been shown to be involved in a variety of cellular processes, including cell adhesion, migration, and invasion. In addition, the CNE9 gene has also been shown to play a role in the regulation of cell apoptosis, which is a natural mechanism that helps remove damaged or dysfunctional cells from the body.

The potential drug target or biomarker qualities of the CNE9 enhancer downstream of SHOX are numerous. The CNE9 gene has been shown to be involved in the regulation of cell proliferation, apoptosis, and other cellular processes, which makes it a potential target for drugs that can inhibit these processes. In addition, the CNE9 gene has also been shown to be involved in the regulation of cell adhesion and migration, which could be useful targets for drugs that can

Protein Name: CNE9 Enhancer Downstream Of SHOX

The "CNE9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNE9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets